LightGBM links a three-protein blood panel to biopsy-staged MASLD fibrosis
A translational study combined a disease-related mouse gene-expression signature, human liver-biopsy transcriptomes and serum protein measurements to select IGFBP7, SSc5D and Sema4D as a three-protein panel for metabolic dysfunction-associated steatotic liver disease (MASLD). A LightGBM model classified biopsy-staged fibrosis, with AUCs 0.82 for F0/F1, 0.89 for F2 and 0.87 for F3/F4 in the development/testing data. In an independent Danish cohort of 156 patients, AUC was 0.84 for F0/F1 and F3/F4; performance for F2 was lower (AUC 0.62).
Technology: LightGBM classifier (TLM3) using the three serum proteins IGFBP7, SSc5D and Sema4D
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A translational study combined a disease-related mouse gene-expression signature, human liver-biopsy transcriptomes and serum protein measurements to select IGFBP7, SSc5D and Sema4D as a three-protein panel for metabolic dysfunction-associated steatotic liver disease (MASLD).
- Still unknown: The model is an early translational biomarker result. Its independent cohort replicated better classification at F0/F1 and F3/F4 (AUC 0.84) but was modest for F2 (AUC 0.62). The authors say mechanistic claims could not be tested in the single-biopsy cohorts and call for prospective and intervention studies before clinical utility is established. TNO disclosed a patent application related to the biomarkers.
- AI role: The LightGBM model combined the three protein measurements selected from a translational mouse/human fibrosis signature to classify liver-biopsy fibrosis stages. The authors compared the model with Fib-4, APRI and FibroScan in held-out and independent cohorts.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11137090/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 70 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.